Literature DB >> 26057761

Clinical Course of Vitreomacular Traction Managed Initially by Observation.

Jonathan H Tzu, Vishak J John, Harry W Flynn, William E Smiddy, Jared R Jackson, Blake A Isernhagen, Adam Carver, Robert Leonard, Homayoun Tabandeh, David S Boyer, Maria H Berrocal, Mihoko Suzuki, K Bailey Freund, Jeffrey G Gross.   

Abstract

BACKGROUND AND
OBJECTIVE: To investigate the clinical course and outcomes of patients with vitreomacular traction (VMT) managed initially by observation. PATIENTS AND METHODS: This noncomparative case series included patients with a diagnosis of VMT based on clinical symptoms and findings on spectral-domain optical coherence tomography (SD-OCT) between 2005 and 2014. VMT was documented using a standardized grading system based on the degree of distortion of the foveal contour. Data were collected at five retina clinics using standardized collection forms. Visual acuity, changes in SD-OCT findings, and timing of the release of VMT as seen on SD-OCT were recorded.
RESULTS: The study included 230 eyes of 185 patients. Mean age was 72.5 years, and mean follow-up was 32 months. At baseline, VMT grading was grade 1 in 92 eyes (40%), grade 2 in 118 eyes (51.3%), and grade 3 in 20 eyes (8.7%). By last follow-up, spontaneous release of VMT occurred in 73 eyes (31.7%). Spontaneous release of VMT occurred at a mean of 18 months (median: 10.9 months) after initial visit. Mean logMAR best corrected visual acuity (BCVA) was 0.28 (20/55) (range: 20/20 to 20/400) at baseline and 0.25 (20/51) (range: 20/20 to 20/400) at last follow-up. Pars plana vitrectomy was performed in 10 eyes (4.1%) for macular hole (six eyes) and increased VMT (four eyes); BCVA was at least 20/40 in eight of the 10 eyes at last follow-up.
CONCLUSION: Patients with VMT generally had a favorable clinical course when managed initially by observation. Spontaneous release of VMT occurred in approximately one-third of patients. At last follow-up, pars plana vitrectomy was performed in fewer than 5% of patients. Copyright 2015, SLACK Incorporated.

Entities:  

Mesh:

Year:  2015        PMID: 26057761     DOI: 10.3928/23258160-20150521-09

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  10 in total

1.  Short-term changes in posterior vitreous cortex following intravitreal ocriplasmin for symptomatic vitreomacular traction syndrome: a prospective study.

Authors:  Andrea Cacciamani; Roberto Gattegna; Marco Pileri; Marta Di Nicola; Sara Bardanzellu; Giuliana Facciolo; Pamela Cosimi; Andrea Govetto; Fabio Scarinci
Journal:  Int Ophthalmol       Date:  2019-09-29       Impact factor: 2.031

2.  The Charles Schepens Lecture: Management Options for Vitreomacular Traction: Use an Individualized Approach.

Authors:  Harry W Flynn; Nidhi Relhan
Journal:  Ophthalmol Retina       Date:  2017 Jan-Feb

3.  PNEUMATIC VITREOLYSIS FOR RELIEF OF VITREOMACULAR TRACTION.

Authors:  Clement K Chan; Jason N Crosson; Calvin E Mein; Noha Daher
Journal:  Retina       Date:  2017-10       Impact factor: 4.256

Review 4.  Pneumatic Vitreolysis for Management of Symptomatic Focal Vitreomacular Traction.

Authors:  Clement K Chan; Calvin E Mein; Jason N Crosson
Journal:  J Ophthalmic Vis Res       Date:  2017 Oct-Dec

5.  Factors Associated with the Clinical Course of Vitreomacular Traction.

Authors:  Petros Petrou; Evangelia Chalkiadaki; Marie-Helene Errera; Sidath Liyanage; Louisa Wickham; Evangelia Papakonstantinou; Aristotelis Karamaounas; Menelaos Kanakis; Ilias Georgalas; Stylianos Kandarakis; David Charteris
Journal:  J Ophthalmol       Date:  2020-12-21       Impact factor: 1.909

6.  Effect of pneumatic vitreolysis in management of patients with symptomatic focal vitreomacular traction.

Authors:  Ahmed N Fouad; Iman M Eissa; Ghada A Nassar; Mahmoud Leila; Adel M Fathy
Journal:  Int J Retina Vitreous       Date:  2022-03-28

7.  Anatomical and functional outcomes of pneumatic vitreolysis for treatment of vitreomacular traction with and without macular holes.

Authors:  Carmen Baumann; Francesco Sabatino; Yalin Zheng; Navid Johannigmann-Malek; Mathias Maier; Stephen B Kaye; Niall Patton
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-02-05       Impact factor: 3.535

8.  Intravitreal ocriplasmin for the treatment of vitreomacular traction and macular hole- A study of efficacy and safety based on NICE guidance.

Authors:  Mahiul M K Muqit; Robin Hamilton; Jason Ho; Sally Tucker; Helen Buck
Journal:  PLoS One       Date:  2018-05-16       Impact factor: 3.240

9.  ASSESSMENT OF ANATOMICAL AND FUNCTIONAL OUTCOMES WITH OCRIPLASMIN TREATMENT IN PATIENTS WITH VITREOMACULAR TRACTION WITH OR WITHOUT MACULAR HOLES: Results of OVIID-1 Trial.

Authors:  Ramin Tadayoni; Frank G Holz; Christophe Zech; Xin Liu; Claudio Spera; Peter Stalmans
Journal:  Retina       Date:  2019-12       Impact factor: 4.256

10.  Defining a Cutoff for Progression of Macular Holes.

Authors:  Carmen Baumann; Saskia Hoffmann; Ahmed Almarzooqi; Navid Johannigmann-Malek; Chris P Lohmann; Stephen B Kaye
Journal:  Transl Vis Sci Technol       Date:  2021-11-01       Impact factor: 3.283

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.